This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Live Webcast Scheduled for January 8, 2013 at 2:45 pm (PST)
EMERYVILLE, Calif., Dec. 19, 2012 (GLOBE NEWSWIRE) -- NovaBay
® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary
Aganocides®, today announced that Dr. Ron Najafi, Chief Executive Officer, will present at the Biotech Showcase 2013, held January 7-9, 2013, in San Francisco, CA. Dr. Najafi will provide detail on the highlights recently announced in NovaBay's
Business Update and 2013 Outlook.
Dr. Najafi and Tom Paulson, Chief Financial Officer, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
Biotech Showcase 2013
Tuesday, January 8, 2013
2:45 pm PST
Parc 55 Wyndham, San Francisco, CA
This presentation will be webcast live and can be accessed on the News & Events section of NovaBay's website at
www.novabay.com . An archive of the presentation will be available for 90 days following this event on the NovaBay website.
About NovaBay Pharmaceuticals, Inc.Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides® and NeutroPhase® Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas.
Aganocide ® Compounds
NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, topical antimicrobials with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides are not subject to bacterial or fungal resistance, which has been demonstrated in in-vitro and in-vivo studies. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas:
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.